DanMRodenMD

PubMed

• 232 citations
  A saturated map of common genetic variants associated with human height.
  Loïc Yengo, Sailaja Vedantam, Eirini Marouli, Julia Sidorenko, Eric Bartell
  Nature. 2022-10-01
• 1439 citations
  Fulminant Myocarditis with Combination Immune Checkpoint Blockade
  Douglas B. Johnson, Justin M. Balko, Margaret L. Compton, Spyridon Chalkias, Joshua M. Gorham
  The New England Journal of Medicine. 2016-11-02
• 665 citations
  Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
  Joe-Elie Salem, Ali Manouchehri, Melissa Y.Y. Moey, Bénédicte Lebrun-Vignes, Lisa Bastarache
  The Lancet. Oncology. 2018-12-01

Journal Articles

• A Case Study Evaluating the Portability of an Executable Computable Phenotype Algorithm Across Multiple Institutions and Electronic Health Record Environments  
  Dan M Roden, Joshua C Denny, Huan Mo, Andy Yizhou Wu, Journal of the American Medical Informatics Association
• The Future of Cardiovascular Therapeutics  
  MacRae CA, Roden DM, Loscalzo J, Circulation, 1/1/2016
• Variants in the SCN5A promoter associated with various arrhythmia phenotypes  
  Yagihara N, Watanabe H, Barnett P, Duboscq-Bidot L, Atack TC, Yang P, Ohno S, Hasegawa K, Kuwano R, Chatel S, Redon R, Schott JJ, Probst V, Koopmann TT, Bezzina CR, Wi..., Heart Rhythm, 1/1/2012
• A common 5'-UTR variant in MATE2-K is associated with poor response to metformin  
  Choi JH, Yee SW, Ramirez AH, Morrissey KM, Jang GH, Joski PJ, Mefford JA, Hesselson SE, Schlessinger A, Jenkins G, Castro RA, Johns SJ, Stryke D, Sali A, Ferrin TE, Wi..., Clin Pharmacol Ther, 1/1/2011
• Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College Of Cardiology Foundation  
  Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W, Circulation, 1/2/2010
• ASCPT remembers Jason Morrow  
  Roden DM, Clin Pharmacol Ther, 1/1/2009
• PharmGKB Submission Update: VII PAT Submissions of Genetic Variation in KCND3 to the PharmGKB Network  
  Simard C, Drolet B, Roden DM, Pharmacol Rev, 1/1/2006
• Genetics of the long QT syndrome  
  Roden DM, ACC Current Journal Review, 1/1/2002
• A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation  
  The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators, N Engl J Med, 1/1/2002
• New approaches to antiarrhythmic therapy: Emerging therapeutic applications of the cell biology of cardiac arrhythmias Part II  
  Members of the Sicilian Gambit, Circulation, 1/1/2001
• New approaches to antiarrhythmic therapy: Emerging therapeutic applications of the cell biology of cardiac arrhythmias Part I  
  Members of the Sicilian Gambit, Circulation, 1/1/2001
• How do we treat arrhythmias in heart failure?  
  Roden DM, Dialogues in Cardiovascular Medicine, 1/1/2000
• Sicilian Gambit: The search for novel antiarrhythmic strategies  
  Members of the Sicilian Gambit, Japanese Circulation J, 1/1/1998
• Cardiovascular drugs: review of mechanisms and clinical applications  
  Roden DM, Willerson JT, Circulation, 1/1/1998
• Cardiovascular and Renal Advisory Panel of the US Food and Drug Administration considers four drugs  
  Roden DM, Circulation, 1/1/1997
• Recent advances in the long QT syndrome  
  Roden DM, Cardiac Electrophysiology Review, 1/1/1997
• Is there a need for new antiarrhythmic drugs?  
  Roden DM, Archives des Maladies du Coeur et des Vaisseaux, 1/1/1996
• Book Review-Cardiovascular Pharmacology and Therapeutics, Singh BN, Dzau VJ, VanHoutte PM, Woosley RL (eds), Churchill Livingstone Inc, New York NY, 1994  
  Roden DM, J Cardiovasc Electrophys, 1/1/1994
• Early afterdepolarizations and torsade de pointes: Implications for the control of cardiac arrhythmias by prolonging repolarization  
  Roden DM, Eur Heart J, 1/1/1993
• The Cardiac Arrhythmia Suppression Trial II Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction  
  Roden DM, N Engl J Med, 1/1/1992
• Drug-induced Torsades de Pointes: Current concepts  
  Wiggins SS, Roden DM, Cardio, 1/1/1992
• Are pharmacokinetics helpful for the clinician?  
  Roden DM, J Cardiovasc Electrophysiol, 1/1/1991
• Task Force of the Working Group on Arrhythmias of the European Society of Cardiology: The Sicilian Gambit: A new approach to the classification of antiarrhythmic drugs...  
  Roden DM, Circulation, 1/1/1991
• CAST: Implications for the use of antiarrhythmic agents in the setting of ischemic heart disease  
  Roden DM, Coronary Artery Disease, 1/1/1991
• Properties of propafenone  
  Roden DM, Funck-Brentano C, Lee JT, Kroemer HK, Cardiology Board Review, 1/1/1991
• Join now to see all

Books/Book Chapters

• Cardiac Potassium Channel Disorders: From Basic to Clinics 
  Chapter: Pharmacogenetics of potassium channel blockers. 
  Roden DMEditors: Shenasa M, Nattel S.Elsevier2016
• Practical Electrophysiology the Drug-Induced Long 
  Chapter: Lidocaine Use in a Patient with Old Myocardial Infarction 
  Page 458 - 460Roden DMEditors: Sra J, Akhtar M, Natale A, Wilbert D.Cardiotext Publishing LLC, Minnneapolis, MN2015
• Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine 
  Chapter: Drug Therapeutics and Personalized Medicine 
  Page 75 - 83Roden DMEditors: Bonow R, Mann D, Zipes D, Libby P.Elsevier, Philadelphia, PAEdition 10th,2014
• Cardiac Sodium Channel Disorders in Cardiac Electrophysiology Clinics 
  Chapter: Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugs. 
  Page 695 - 704Roden DMEditors: Abriel H.Elsevier2014
• Principles of Pharmacogenetics and Pharmacogenomics 
  Chapter: Genomics of the Drug-Induced Long-QT Syndrome 
  Page 136 - 144Roden DMEditors: Altman R, Flockhart D, Goldstein D.Cambridge University Press, New York, NY2012
• Harrison's Principles of Internal Medicine 
  Chapter: Principles of Clinical Pharmacology. 
  Page 13 - 25Roden DMMcGraw-HillEdition 18th,2011
• Clinical and Translational Science, Principles of Human Research 
  Chapter: Toxicology and Genetics of Adverse Events 
  Page 339 - 344Roden DMEditors: Robertson D, Williams G.Elsevier, San Diego, CA2009
• Pharmacology and Therapeutics, Principles to Practice 
  Chapter: Therapy of Rhythm Disorders 
  Page 367 - 387Darbar D, Roden DMEditors: Waldman S and Terzic A.Elsevier, Philadelphia, PA2009
• Encyclopedia of Molecular Mechanisms of Disease 
  Chapter: Cardiac Arrest. 
  Page 271 - 272Watanabe H, Roden DM2008
• Comprehensive Cardiovascular Medicine 
  Chapter: Antiarrhythmic drugs 
  Page 1151 - 1165Roden DMEditors: Topol E.Lippincott-Raven, Philadelphia, PAEdition 3rd,2006
• Cardiovascular Medicine 
  Chapter: Antiarrhythmic drugs. 
  Page 2085 - 2102Roden DM, Darbar D, Kannankeril PJEditors: Willerson JT, Cohn JN, Wellens HJJ, Holmes DR.Springer Verlag, LondonEdition 3rd,2006
• Pharmacogenomics 
  Chapter: Pharmacogenetics and Cardiac Ion Channels 
  Page 207 - 220Roden DMEditors: Kalow W, Meyer UA, and Tyndale RF.Taylor and Francis, Boca Raton, FL2006
• Basis and Treatment of Cardiac Arrhythmias, Handbook of Experimental Pharmacology 
  Chapter: Proarrhythmia 
  Page 73 - 97Roden DM, Anderson MEEditors: Kass RS and Clancy CE.Springer Verlag, Berlin2006
• Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine 
  Chapter: The Principles of Drug Therapy 
  Page 43 - 52Roden DMEditors: Zipes D, Libby P, Bonow R, Braunwald E.Elsevier, Philadelphia, PAEdition 7th,2005
• Harrison's Principles of Internal Medicine 
  Chapter: Principles of Clinical Pharmacology 
  Page 13 - 25Roden DMMcGraw-HillEdition 16th,2005
• Sudden Cardiac Death: A Handbook for Clinical Practice 
  Chapter: Drug-Induced Sudden Death 
  Page 177 - 188Roden DM, Drici MDEditors: Priori S and Zipes DP.Blackwell Scientific2005
• Goodman and Gilman's The Pharmacological Basis of Therapeutics 
  Chapter: Antiarrhythmic drugs. 
  Page 899 - 932Roden DMEditors: Brunton LL, Laso JS, Parker KL.McGraw-Hill, New YorkEdition 11th,2005
• New Arrhythmia Technologies 
  Chapter: Principles of pharmacogenetics: focus on arrhythmias. 
  Page 31 - 35Roden DMEditors: Wang P.J..Blackwell Futura, Malden, MA2005
• Electrophysiological Disorders of the Heart 
  Chapter: Molecular and cellular basis of cardiac electrophysiology. 
  Page 1 - 31Tomaselli G, Roden DMEditors: Saksena S, Camm AJ.Elsevier, Philadelphia, PA2005
• Cardiac Electrophysiology: From Cell to Bedside 
  Chapter: Pharmacogenomics of Cardiac Arrhythmias and Impact on Drug Therapy 
  Page 471 - 477Roden DMEditors: Zipes DP, Jalife J.W.B. Saunders, Philadelphia, PAEdition 4th,2003
• Cardiovascular Pharmacogenetics; Handbook of Experimental Pharmacology 
  Chapter: The Genetics of Cardiac Channelopathies: Implications for Therapeutics 
  Page 223 - 241Roden DMEditors: Wilkins M.Springer, Berlin2003
• Primer on the Autonomic Nervous System 
  Chapter: The Autonomic Nervous system and Sudden Cardiac Death 
  Page 245 - 246Roden DMEditors: Robertson D, et al.Academic PressEdition 2nd,2003
• A Textbook of Cardiology 
  Chapter: Disorders of Cardiac Repolarization: The Long QT Syndromes 
  Page 1 - 10Murray KT and Roden DMEditors: Dimarco J and Crawford M.Mosby2001
• A Textbook of Cardiology 
  Chapter: Basic Cardiac Electrophysiology and Anatomy 
  Page 1 - 12Anderson ME and Roden DMEditors: Dimarco J and Crawford M.Mosby2001
• Harrison's Principles of Internal Medicine 
  Chapter: Principles of Drug Therapy. 
  Page 419 - 430Oates JA, Roden DM, Wilkinson GRMcGraw-HillEdition 15th,2001
• Join now to see all

Abstracts/Posters

• Genomic editing in iPSCs establishes that a rare TBX5 variant causes Brugada syndrome.
  Bersell K, Yang T, Hong CC, Petropolulou E, Jamshidi Y, Wells QS, Kannankeril PJ, Roden DM, Student Platform Presentation, ASCI-AAP Annual Meeting, 1/1/2016
• Genomic editing in IPSCs establishes that a rare TBX5 variant casues Brugada syndrome.
  Bersell K, Yang T, Hong CC, Petropolulou E, Jamshidi Y, Wells QS, Kannankeril PJ, Roden DM, Heart Rhytm, 1/1/2016
• Extended GWAS In Brugada Syndrome Uncovers Additional Risk Alleles At The SCN5A/SCN10A Locus With Marked Cumulative Effects On Risk For The Disorder.
  Barc J, Mizusawa Y, Dina C, Gourraud JB, Simonet F, Behr ER, Schulze-Bahr E, Nuyens D, Saenen J, Lambiase PD, Guicheney P, Borggrefe MM, Antzelevitch C, Kaab S, Tfelt-..., Heart Rhytm, 1/1/2016
• Mice with the common SCN5Avariant S1103Y are highly susceptible to arrhythmias on provocation.
  Yang T, Daniel LL, Roden DM, Heart Rhytm, 1/1/2016
• Genome-wide association study of platelet factor 4/heparin antibody formation. ASCPT 2015.
  Karnes JH, Denny JC, Bowton EA, Shaffer CM, Mosley JD, VanDriest S, Weeke PE, Wells QS, Roden DM, Clinical Pharmacology and Therapeutics, American Society for Clinical Pharmacology & Therapeutics (ASCPT), 1/1/2015
• A pharmacogenomics approach combined with various genetic analyses uncovers genes linked to the dynamics of HBA1C.
  Goswami S, Yee S, Mosley J, Hedderson M, Kabu M, Maeda S, Roden DM, Simpson MD, Giacomini KM, Savic RM, Clinical Pharmacology and Therapeutics, American Society for Clinical Pharmacology & Therapeutics (ASCPT), 1/1/2015
• 4q25 Atrial Fibrillation Susceptibility Alleles Predict Typical Atrial Flutter in Patients Undergoing Ablation for Atrial Fibrillation.
  Yoneda Z, Montgomery J, Lugo R, Aznaurov S, Parvez B, Adkins K, Whalen SP, Roden D, Estrada JC, Kanagasundram A, Saavedra P, Ellis C, Darbar D, Shoemaker MB, Heart Rhythm, Heart Rhythm Society, 1/1/2015
• Cavotricuspid Isthmus Ablation and Reduction of Atypical Atrial Tachycardia and Flutter Following Catheter-based Ablation for Atrial Fibrillation.
  Montgomery J, Yoneda Z, Lugo R, Aznaurov S, Parvez B, Adkins K, Whalen SP, Roden D, Estrada JC, Kanagasundram A, Saavedra P, Ellis C, Darbar D, Shoemaker MB, Heart Rhythm, Heart Rhythm Society, 1/1/2015
• Inhibition of the alpha-subunit of PI3 kinase increases late sodium current (INa-L) and generates arrhythmias.
  Yang T, Hong CC, Roden DM, Heart Rhythm, 1/1/2015
• UGT1A Polymorphisms and Simvastatin Efficacy in Routine Clinical Care.
  Iwuchukwu OF, Jiang L, Feng Q, Wei-Qi W, Roden DM, Stein CM, Wilke RA, American Society for Clinical Pharmacology and Therapeutics, 1/1/2014
• MTRNR1 Aminoglycoside Variants in a Pediatric Population.
  McGregor TL, Kannankeril P, Smith A, Roden D, American College of Medical Genetics, 1/1/2014
• External Validation of a Prediction Model for the Development of Atrial Fibrillation in a Repository of Electronic Medical Records.
  Kolek MJ, Graves AJ, Bian A, Teixeira PL, Shoemaker BM, Parvez B, Xu H, Heckbert SR, Ellinor PT, Benjamin EJ, Alonso A, Denny JC, Moons KGM, Shintani AK, Roden DM, Dar..., Circulation, AHA 2014 Scientific Session, 1/1/2014
• Both Common and Rare SCN10A Variants Associated with Brugada Syndrome Displayed an Increase in Late Nav1.8 Sodium Currents in ND 7/23 cells.
  Savio-Galimberti E, Yang T, Roden D, Behr ER, Kor KC, Jamshidi Y, Petropoulou E, Guicheney P, Tfelt-Hansen J, Wilde AAM, Bezzina CR, Olesen MS, Holst AG, Ackerman MJ, ..., Circulation, AHA 2014 Scientific Session, 1/1/2014
• Influence of Exonic Variation on Heparin-Induced Thrombocytopenia.
  Karnes JH, Denny JC, Cronin RM, Shaffer CM, Bowton EA, Cowan JD, Mosley JD, Van Driest SL, Weeke PE, Wells QS, Roden DM, Circulation, AHA 2014 Scientific Session, 1/1/2014
• Examining Rare and Low-Frequency Genetic Variants Previously Associated With Lone or Familial Forms of Atrial Fibrillation in an Electronic Medical Record System: A Ca...
  Weeke P, Denny JC, Basterache L, Shaffer C, Bowton E, Ingram C, Darbar D, Roden DM, Circulation, AHA 2014 Scientific Session, 1/1/2014
• Modeling of a Rare SCN10A Variant (A1886V) Linked with Early-Onset Atrial Fibrillation Shortens Atrial Action Potential Duration.
  Abraham RL, Savio-Galimberti E, Yang T, Roden DM, Darbar D, Circulation, AHA 2014 Scientific Session, 1/1/2014
• Cellular and Functional Defects Contributing to Dilated Cardiomyopathy in SCN5A D1275N Mice.
  Stroud DM, Hall L, Hwang HS, Baudenbacher F, Knollmann B, Roden DM, Circulation, AHA 2014 Scientific Session, 1/1/2014
• Comprehensive Evaluation of QT Interval During Abrupt Changes in Heart Rate and Associated Neurohormonal and Inflammatory Markers.
  Kolek MJ, Parvez B, Song Y, Abraham RL, Roden DM, Darbar D, Circulation, AHA 2014 Scientific Session, 1/1/2014
• A Clinical Decision Aid to Identify Emergency Department Patients With Atrial Fibrillation at Low Risk for 30-Day Adverse Events.
  Barrett TW, Storrow AB, Jenkins CA, Abraham RA, Liu D, Miller KF, Moser K, Russ S, Roden DM, Harrell Jr. FE, Darbar D, Circulation, AHA 2014 Scientific Session, 1/1/2014
• Association of rare variants in LDLR, HMGCR, NAT2, ABCA1, and APOA1 with plasma lipid levels; initial results from the eMERGE PGx project.
  Kullo IJ, Bielinski SJ, Carrell DS, Stallings S, Pathak J, Gordon A, Rasmussen-Torvik L, Dohney KF, Volpi S, Ritchie MD, Denny JC, Chute CG, Roden DM, Nickerson DA, Ja..., American Society for Human Genetics 2014 Scientific Sessions, 1/1/2014
• Rare potentially pathogenic variants in the congenital arrhythmia syndrome disease genes SCN5A and KCNH2 are detected frequently but rarely associated with arrhythmia ...
  Van Driest SL, Stallings S, Bush WS, Gordon A, Crosslin DR, Jarvik GP, Carrell DS, Bielinski SJ, Olson JE, Ye Z,Kullo IJ, Abul-Husn NS, Scott SA, Castillo BA, Connolly..., American Society for Human Genetics 2014 Scientific Sessions, 1/1/2014
• A genome-wide association study identified variants in KCNIP4 associated with ACE inhibitor induced cough.
  Mosley JD, Shaffer CM, Van Driest SL, Weeke PE, Wells QS, Karnes JH, Velez-Edwards DR, Wei W, Teixeira PL, Bastarache L, Crawford DC, Pacheco JA, Manolio TA, Bottinger..., American Society for Human Genetics 2014 Scientific Sessions, 1/1/2014
• CTNNA3 and SEMA3D: Promising loci for asthma exacerbation identified through multiple cohorts.
  McGeachie MJ, Wu AC, Tse SM, Clemmer GL, Sordillo J, Weeke P, Shaffer C, Denny J, DM Roden, Raby BA,Weiss ST, Tantisira KG, American Society for Human Genetics 2014 Scientific Sessions, 1/1/2014
• A genome-wide association study of hepatic toxicity of methotrexate therapy for rheumatoid arthritis.
  Mo H, Braggs N, Bastarache L, Carroll RJ, Roden D, Raychaudhuri S, Karlson EW, Denny JC, American Society for Human Genetics 2014 Scientific Sessions, 1/1/2014
• Clinician Views about Implementation of Pharmacogenomics into Practice.
  Peterson JF, Field JR, Shi Y, Schildcrout JS, Denny J, McGregor T, Van Driest S, Pulley J, Lubin I, Laposata M, Roden DM, Clayton EW, American Society for Human Genetics 2014 Scientific Sessions, 1/1/2014
• Join now to see all

Lectures

• Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment 
  American Heart Association, Scientific Sessions 2010, Chicago, Illinois, USA
• International Conference on Intelligent Biology and Medicine (ICIBM 2013) 
  Vanderbilt University Medical Center(VUMC), Nashville, Tennessee - 8/11/2013

Other

• Implementing Genomic Medicine Globally: We Are Not Alone. 
  Manolio TA, Abramowicz M, Al-Mulla F, Anderson W, Balling R, Berger AC, Chakravarti A, Chantratita W, Chisholm RL, Dissanayake VHW, Dzau VJ, Frebourg T, Han BG, Hubbar..., Science Translational Medicine
  1/3/2015
• Issues expanding in the field of pacing arrhythmia. 
  Roden DM, Today in Cardiology
  1/1/2004
• Atrial Fibrillation. 
  Roden DM, EBM Solutions Guidelines for Health Care Providers and Consumers (online database), Issue 1
  Nashville TN - 1/1/2000
• Encainide and related new antiarrhythmic drugs. 
  Roden DM, ISI Atlas of Science
  1/1/1988
• Pharmacology and clinical use of encainide. 
  Roden DM, Woosley RL, IM
  1/1/1987
• Quinidine-associated long QT syndrome. 
  Roden DM, Woosley RL, Primm RK, Cardiology Board Review
  1/1/1987
• Multiple therapy with cardiac drugs. 
  Roden DM, Woosley RL, American Associa­tion for Clinical Chemistry, Therapeutic Drug Monitoring, pp. 1-2
  1/1/1983
• Clinical evaluation of antiarrhythmic drug therapy. 
  Roden DM, Woosley RL, American Association for Clinical Chemistry, Therapeutic Drug Monitoring, pp. 1-6
  1/1/1982
• Active drug metabolites: Monitoring and interpretation 
  Roden DM, Woosley RL, American Associa­tion for Clinical Chemistry, Therapeutic Drug Monitoring, pp. 1-3
  1/1/1981
• Join now to see all